SS Innovations International Inc. (NASDAQ: SSII) has brought robotic cardiac surgery to Sri Lanka with the launch of the country's first robotic cardiac surgery program at Kings Hospital Colombo. The program utilizes the SSi Mantra 3.0 surgical robotic system and began with a robotic-assisted left internal mammary artery (LIMA) takedown performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This development was highlighted in a recent company video.
The introduction of robotic cardiac surgery in Sri Lanka represents a significant advancement for the country's healthcare sector. Robotic-assisted procedures offer the potential for smaller incisions, reduced pain, shorter hospital stays, and faster recovery times compared to traditional open-heart surgery. By bringing this technology to Sri Lanka, SS Innovations is helping to elevate the standard of cardiac care in the region and provide patients with access to minimally invasive options that were previously unavailable.
Kings Hospital has completed more than 25 robotic procedures in just three weeks, according to the company video. This rapid adoption demonstrates both the feasibility and the demand for robotic surgery in Sri Lanka. The successful implementation of the program could serve as a model for other hospitals in the region, potentially leading to broader adoption of robotic-assisted surgery across South Asia.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, indicating rising utilization of the company's installed base. These figures underscore the growing global footprint of SS Innovations and the increasing acceptance of its robotic surgical platform.
The next major corporate milestone for SS Innovations is regulatory expansion, with the company pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open up significant new markets and further accelerate the company's growth. The successful launch in Sri Lanka adds to the company's expanding international presence and demonstrates the versatility of the SSi Mantra system in performing complex cardiac procedures.
For investors, the expansion into Sri Lanka and the positive procedural numbers suggest that SS Innovations is effectively executing its strategy to penetrate new markets and drive adoption of its robotic surgery platform. The company's ability to support the launch of a new cardiac surgery program in a country where such technology was previously unavailable highlights the potential for further geographic expansion. As SS Innovations continues to pursue regulatory approvals in the U.S. and Europe, the successful implementation in Sri Lanka serves as a proof point for the system's capabilities and the company's ability to support complex surgical programs.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
